TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference
February 09, 2022 06:45 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients...
TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer
January 12, 2022 06:45 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones
January 10, 2022 06:45 ET
|
TCR2 Therapeutics
- Safety Review Team (SRT) identified gavo-cel recommended Phase 2 dose (RP2D) at 1x108 cells/m2- Initiation of gavo-cel Phase 2 study expected in 1H 2022 with initial data in 2H 2022- Initial data...
TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference
January 07, 2022 17:00 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- https://investors.tcr2.com/ TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell...
TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference
January 05, 2022 06:45 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients...
TCR² Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies
January 04, 2022 07:00 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients...
TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 10, 2021 06:45 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients...
TCR² Therapeutics Announces Expansion of U.S. Manufacturing Capacity
November 01, 2021 16:05 ET
|
TCR2 Therapeutics
- Second clean room at ElevateBio BaseCamp will expand cGMP capacity for clinical trials in 2022 - Future network to focus on TCR2 manufacturing center of excellence in Rockville, MD - Strategy...
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors
October 25, 2021 06:45 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day
October 20, 2021 06:45 ET
|
TCR2 Therapeutics
- gavo-cel recommended Phase 2 dose (RP2D) identification before year-end - Anticipated IND filing for TC-510 in 1Q22 - Identification of CD70-targeted lead candidate - Anticipated allogeneic...